--- title: Idexx Laboratories (IDXX) — intrinsic value and fair price canonical: https://sweetvaluelab.com/stocks/idxx ticker: IDXX as_of: 2026-10-17 sector: Healthcare industry: Medical - Diagnostics & Research --- # Idexx Laboratories (IDXX) Idexx Laboratories (IDXX) closed at $560.36 on Oct 16, 2026, overvalued by 152% vs its model value of $222.36 (from a five-year discounted cash flow). ## Key figures | Figure | Value | | --- | ---: | | Last close | $560.36 (Oct 16, 2026) | | Model value (from a five-year discounted cash flow) | $222.36 | | Price vs model | overvalued by 152% vs model | | Range of that model | $161.81 – $368.35 | | Market value | $44.1B | | P/E (fiscal 2025) | 42.8 | | Net margin (fiscal 2025) | 24.6% | | Free cash flow (fiscal 2025) | $1.1B | | Dividend yield (trailing twelve months) | 0.00% | | Beta | 1.55 | | Cost of capital (WACC) | 10.71% | | Business classification | Profitable Growth (Low/slowing growth (~8% recent), High profitability (25% net margin), Moderately volatile earnings) | ## Valuation models Each model's value per share and the role the engine gave it for this business. The headline above is one model's value; every other model is listed with its own, and each has a page of its own under the valuation. Computed Oct 17, 2026. | Model | Role | Value per share | Low | High | | --- | --- | ---: | ---: | ---: | | DCF · Perpetuity growth · 5y | primary | $222.36 | $161.81 | $368.35 | | DCF · Perpetuity growth · 10y | cross check | $246.17 | $182.31 | $397.23 | | DCF · EBITDA exit · 5y | cross check | $306.29 | $221.25 | $406.10 | | DCF · EBITDA exit · 10y | cross check | $313.83 | $226.14 | $429.86 | | P/E · peers | cross check | $355.87 | $178.33 | $533.40 | | P/E · own history | cross check | $696.87 | $604.72 | $832.65 | | PEG | sanity check | $212.31 | $212.31 | $212.31 | | EV/EBITDA · peers | cross check | $256.83 | $234.10 | $338.08 | | EV/Revenue · peers | cross check | $238.57 | $190.71 | $332.82 | | Earnings power value | cross check | $89.99 | $78.53 | $105.18 | | Dividend discount | cross check | $0.00 | $0.00 | $0.00 | ## Insider activity (SEC Form 4) Past 90 days: 0 open-market buys ($0) and 1 open-market sale ($1.2M); 10b5-1 plan sales included. | Date | Insider | Relationship | Transaction | Shares | Value | | --- | --- | --- | --- | ---: | ---: | | Sep 4, 2026 | Kingsley Lawrence D | Director | Option/RSU exercise | 2,203 | $251,516.5 | | Sep 4, 2026 | Kingsley Lawrence D | Director | Open-market sell | 2,203 | $1.2M | | Sep 4, 2026 | Kingsley Lawrence D | Director | Option/RSU exercise | 2,203 | — | | Aug 20, 2026 | Emerson Andrew | EVP, CFO and Treasurer | Option/RSU exercise | 265 | $47,238.9 | | Aug 20, 2026 | Emerson Andrew | EVP, CFO and Treasurer | Tax withholding | 86 | $0 | ## Recent SEC filings | Filed | Form | What | Filing | | --- | --- | --- | --- | | Aug 4, 2026 | 8-K | 2.02 Results of Operations (Earnings); 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/874716/000110465926090033/tm2622041d1_8k.htm | | Aug 4, 2026 | 10-Q | Quarterly report | https://www.sec.gov/Archives/edgar/data/874716/000087471626000123/idxx-20260630.htm | | May 15, 2026 | 8-K | 5.03 Amendment to Articles/Bylaws; 5.07 Submission of Matters to a Shareholder Vote; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/874716/000087471626000110/idxx-20260512.htm | | May 5, 2026 | 8-K | 2.02 Results of Operations (Earnings); 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/874716/000110465926055203/tm2613510d1_8k.htm | | May 5, 2026 | 10-Q | Quarterly report | https://www.sec.gov/Archives/edgar/data/874716/000087471626000076/idxx-20260331.htm | ## Superinvestors holding it (latest 13F) | Manager | Quarter | Shares | Value | | --- | --- | ---: | ---: | | Terry Smith | 2026-06-30 | 1,019,887 | $536.9M | | Polen Capital | 2026-06-30 | 532,384 | $280.3M | | Jensen | 2026-06-30 | 105,709 | $55.6M | | Wallace Weitz | 2026-06-30 | 35,300 | $18.6M | 7 tracked managers in all. ## About IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biol… --- Source: https://sweetvaluelab.com/stocks/idxx (SweetValueLab, free, no account). Prices and statements from Financial Modeling Prep; filings from SEC EDGAR. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.